- Strong Q1 Performance: Abbott Laboratories reported an EPS of $1.15, surpassing analyst estimates of $1.14, and revenue of $11.16 billion, beating expectations of $11.00 billion.
- Strategic Growth Initiatives: The positive results were driven by robust medical device sales and early benefits from the acquisition of Exact Sciences, positioning the company in the growing cancer diagnostics market.
- Positive Outlook and Stable Valuation: The company updated its full-year sales growth forecast to between 6.5% and 7.5%, reflecting confidence, and maintains stable financial health with a low debt-to-equity ratio of 0.29.
On April 16, 2026, Abbott Laboratories (NYSE: ABT) reported its first-quarter earnings. The company is a global healthcare company that operates in several areas, including medical devices, diagnostics, nutrition products, and established pharmaceuticals. The company’s recent performance provides insight into its current financial standing and strategic direction.
Abbott Laboratories announced an earnings per share (EPS) of $1.15, which is a key measure of a company’s profitability. This figure surpassed the consensus analyst estimate of $1.14. As highlighted by Zacks, this result also shows growth compared to the $1.09 per share that Abbott Laboratories earned in the same quarter one year prior.
The company also reported strong revenue of $11.16 billion, beating the expected $11.00 billion. According to Reuters, this positive outcome was driven by strong sales in its medical device segment. The performance was also helped by its newly acquired cancer diagnostics business, showing early benefits from the company’s recent expansion.
A major event for Abbott Laboratories was the completed acquisition of Exact Sciences. As noted by PR Newswire, this strategic move positions the company as a leader in the growing cancer diagnostics market. Following this, Abbott Laboratories updated its full-year sales growth forecast to between 6.5% and 7.5%, reflecting confidence in its expanded portfolio.
From a valuation standpoint, Abbott Laboratories has a Price-to-Earnings (P/E) ratio of 26.00, which compares its stock price to its earnings. The company’s financial health appears stable, with a low debt-to-equity ratio of 0.29. This ratio indicates that the company uses less debt than equity to finance its assets.
